Insulin aspart (Fiasp) vs SAR341402

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (Fiasp)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

SAR341402

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT03211858 · Phase 3 · completed

The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.

Reported efficacy

Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)

Result source: NCT03211858

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (Fiasp)SAR341402
HbA1c, change6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858
Body weight, change (kg)1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005—Not reported
HbA1c below 7%—Not reported19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858
Fasting plasma glucose, change0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Insulin aspart (Fiasp)
6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
SAR341402
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858

Body weight, change (kg)

Insulin aspart (Fiasp)
1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005
SAR341402
—Not reported

HbA1c below 7%

Insulin aspart (Fiasp)
—Not reported
SAR341402
19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858

Fasting plasma glucose, change

Insulin aspart (Fiasp)
0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005
SAR341402
-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858

3-point MACE (% with event)

Insulin aspart (Fiasp)
—Not reported
SAR341402
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (Fiasp): 4 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin aspart (Fiasp)
Rows use multiple source trials
SAR341402
Dropout rate
12.8%a
NCT01819129 · Phase 3
show 2 more results
7.8%
NCT01850615 · Phase 3 · combination
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
12.3%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Discontinued due to AEs
0.3%a
NCT01819129 · Phase 3
show 2 more results
1.7%
NCT01850615 · Phase 3 · combination
—
NCT03268005 · Phase 3 · registry result, not featured evidence
2.7%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Serious AEs
4.4%a
NCT01819129 · Phase 3
show 2 more results
5.2%
NCT01850615 · Phase 3 · combination
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
12%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Most frequent reported AEs
a
urinary tract infection 5.9%
nasopharyngitis 5%
upper respiratory tract infection 4.7%
NCT01819129 · Phase 3
show 2 more results
diarrhoea 1.7%
NCT01850615 · Phase 3 · combination
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11.3%
upper respiratory tract infection 7.3%
influenza 5%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin aspart (Fiasp)

PPG Excursion 4.55 vs 4.9 NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT01819129 · Phase 3
show 1 more result
-0.43 vs 0.08 NovoRapid mmol/L @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 49.6% (n=546) vs 51.7% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 271 Participants as posted
HbA1c Less Than 7 Without Severe Hypoglycemia 48.5% (n=546) vs 51% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 265 Participants as posted
SMBG Daily Average -0.56 vs -0.5 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
SMPG-mean Post Prandial Increment -0.48 vs -0.23 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
All meals
NCT03268005 · Phase 3 · registry result, not featured evidence
Postprandial Glucose Leq 7.8 34.1% (n=546) vs 35.2% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 186 Participants as posted
Postprandial Glucose Leq 7.8 mmol/L Without Severe Hypoglycemia 33.3% (n=546) vs 34.9% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 182 Participants as posted
Weight 1.19 vs 1.12 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence
BMI 0.43 vs 0.4 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence

SAR341402

HbA1c Less Than 7% 16.6% (n=301) vs 14.5% (n=296) NovoLog/NovoRapid @ 26wk
responder rate · % of participants
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
19.6% (n=301) vs 18.2% (n=296) NovoLog/NovoRapid @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Daily Plasma Glucose -0.34 vs -0.53 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
0.12 vs -0.18 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · SAR341402's landscape